Árni Blöndal is partner at Brunnur Ventures, with more than 25 years of international investment experience across over 10 countries, including 15 years as a fund manager across three venture funds, eight years in corporate finance advisory, and two years as a startup co-founder. He has served as a board member in more than 20 early stage companies, with a focus on biotech / healthtech.

At Oculis SA, an ophthalmology drug development company, Árni led the seed round in Oculis in 2016 and served on the board until 2023. During his tenure, Oculis grew from four to 36 employees across four countries, advanced from Phase 2 to Phase 3 clinical trials, secured 192 million dollars in funding, and ultimately listed on Nasdaq New York, reaching a market capitalization of approximately 1.2 billion dollars as of January 2026.

Árni brings hands on experience in biotech company building, clinical stage value creation, syndicate formation, fundraising, and key executive hiring.